Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4 + T cells [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 5, 2004, Pages 1103-1104

  Lehrman, Ginger ^a   Ylisastigui, Loyda ^a   Bosch, Ronald J ^b   Margolis, David M ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 7;

ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; INFECTION; LATENT PERIOD; LETTER; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIREMIA;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; G0 PHASE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-7; RECEPTORS, INTERLEUKIN-7; VIRUS ACTIVATION;

EID: 3343003471     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408150-00015     Document Type: Letter

References (21)

1. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science. 1998;280:1866-1867.
2. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA. 1999;96:10958-10961.
3. Butera ST. Therapeutic targeting of human immunodeficiency virus type-1 latency, current clinical realities and future scientific possibilities. Antiviral Res. 2000;48:143-176.
4. Pomerantz RJ. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication. Clin Infect Dis. 2002;34:91-97.
5. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-593.
6. Chun TW, Stayver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193-13197.
7. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
9. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest. 2000;106:839-845.
10. Chun TW, Davey RT Jr, Ostrowski M, et al. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med. 2000;6:757-761.
11. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
12. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
13. Brooks DG, Kitchen SG, Kitchen CM, et al. Generation of HIV latency during thymopoiesis. Nat Med. 2001;7:459-464.
14. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity. 2003;19:413-423.
15. Coull JJ, He G, Melander C, et al. Targeted derepression of the human immunodeficiency type 1 virus long terminal repeat by pyrrole-imidazole polyamides. J Virol. 2002;76:12349-12354.
16. Ylisastigui L, Archin NM, Lehrman G, et al. Coaxing human immunodeficiency virus type 1 from resting CD4+ T cells: can the reservoir of HIV be purged? AIDS. (In press).
17. Ylisastigui L, Coull JJ, Rucker V, et al. Polyamides reveal a role for repression in viral latency within HIV-infected donors' resting CD4+ T cells. J Infectious Diseases. (In press).
18. Scripture-Adams DD, Brooks DG, Korin YD, et al. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002;76:13077-13082.
19. Pierson T, Huffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol. 2000;74:7824-7833.
20. Chun T-W, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
21. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol. 1994;32:732-739.